Tuparstobart is an Fc-engineered IgG1-kappa monoclonal antibody that binds the co-inhibitory receptor LAG-3 on tumor-infiltrating lymphocytes. It blocks LAG-3 interaction with MHC class II molecules, relieving suppression of T-cell activity. It is being studied in head and neck cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
INCAGN-02385, AGEN-2385
Drug type
Monoclonal antibody
Targets
lymphocyte-activation gene 3 protein (LAG3), major histocompatibility complex class II (MHC II) (binding partner it blocks)
Mechanism
Antagonist of lymphocyte-activation gene 3 protein (LAG3)
Pathways
LAG-3-MHC II interaction blockade, T-cell activation, cytotoxic T-lymphocyte response
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.